ArticleBJU international2020
Waterjet Ablation Therapy for Endoscopic Resection of prostate tissue trial (WATER) vs WATER II: comparing Aquablation therapy for benign prostatic hyperplasia in 30-80 and 80-150 mL prostates.
Article in BJU international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Multicenter Randomized Blinded Study Comparing Aquablation of the Prostate With the AQUABEAM System and TURP for the Treatment of LUTS
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Ejaculatory function after robotic waterjet ablation for the treatment of benign prostatic hyperplasia: a systematic review.International journal of impotence research · 2026Pooled it
- Complication Profile and Safety Outcomes of Aquablation in the Management of BPH.Medicina (Kaunas, Lithuania) · 2025Pooled it
- Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.World journal of urology · 2022Pooled it
- Aquablation/AquaBeam Waterjet Therapy for Benign Prostatic Hyperplasia: Three-Year Functional and Ejaculatory Outcomes in a Multicenter Real-World Italian Cohort.Lower urinary tract symptoms · 2026Article
- Editorial Comments to "Optimizing Patient Selection for Aquablation During the Initial Adoption Phase: Prostates Smaller Than 100 mL".International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Investigation on the cutting-infiltration integrated strategy based on medical waterjet for targeted drug delivery.Scientific reports · 2026Article
- A Narrative Review of Robotic Aquablation in Benign Prostatic Hyperplasia Care: Where We Are Now.Cureus · 2025Review
- Tissue-Selective Separation Mechanism of Multi-type Soft Tissues Under Waterjet Impact for Low-Trauma Cutting Surgery.Annals of biomedical engineering · 2025Article
- Efficacy, feasibility, and safety of aquablation after previous urolift treatment of lower urinary tract symptoms secondary to benign prostate hyperplasia: a retrospective cohort study.World journal of urology · 2025Article
- Application of robotics in the treatment of benign prostatic hyperplasia: a narrative review.Prostate international · 2025Review
- A flexible cystoscopy device prototype for mechanical tissue ablation based on micro-scale hydrodynamic cavitation: Ex vivo and in vivo studies.Ultrasonics sonochemistry · 2025Article
- The Impact of Transurethral Enucleation Therapeutic Approach in All-Size Benign Prostatic Obstruction Pathology: From Contemporary Technological Advances to Evidence-Based Clinical Progresses.Diagnostics (Basel, Switzerland) · 2025Review
- Aquablation, a safe technique?Central European journal of urology · 2025Article
- WATER versus WATER II 5-year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30-80-cmBJUI compass · 2024Article
- Ablative minimally invasive surgical therapies for benign prostatic hyperplasia: A review of Aquablation, Rezum, and transperineal laser prostate ablation.Prostate cancer and prostatic diseases · 2024Review
- Evaluating the Impact of Benign Prostatic Hyperplasia Surgical Treatments on Sexual Health.Biomedicines · 2024Review
- Artificial intelligence: A new tool in surgeon's hand.Journal of education and health promotion · 2022Review
- A Practical Approach for Primary Care Practitioners to Evaluate and Manage Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Review
- Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience.World journal of urology · 2021Article
- Initial single centre experience of Aquablation of the prostate using the AquaBeam system with athermal haemostasis for the treatment of benign prostatic hyperplasia: 1-year outcomes.World journal of urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 15 institutions in 5 countries.
Funding
Abstract
objectiveTo compare the outcomes of Aquablation in 30-80 mL prostates with those in 80-150 mL prostates. Surgical options, especially with short learning curves, are limited when treating large prostates for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Aquablation (AquaBeam System, PROCEPT BioRobotics Inc., Redwood City, CA, USA) could solve this issue with global reproducibility, independent of prostate volume. PATIENTS AND
methodsWaterjet Ablation Therapy for Endoscopic Resection of prostate tissue (WATER [W-I]; NCT02505919) is a prospective, double-blind, multicentre, international clinical trial comparing Aquablation and transurethral resection of the prostate (TURP) for the treatment of LUTS/BPH in prostates between 30 and 80 mL. WATER II (W-II; NCT03123250) is a prospective, multicentre, single-arm international clinical trial of Aquablation in prostates between 80 and 150 mL. We compare baseline parameters and 12-month outcomes in 116 W-I and 101 W-II study patients. Students' t-test or Wilcoxon tests were used for continuous variables and Fisher's test for binary variables.
resultsThe mean (SD) operative time was 33 (17) and 37 (13) min in W-I and W-II, respectively. Actual treatment time was 4 and 8 min in W-I and W-II, respectively. The mean change in the International Prostate Symptom Score was substantial averaging (at 12 months) 15.1 in W-I and 17.1 in W-II (P = 0.605). By 3 months, Clavien-Dindo grade ≥II events occurred in 19.8% of W-I patients and 34.7% of W-II patients (P = 0.468).
conclusionAquablation clinically normalises outcomes between patients with 30-80 mL prostates and patients with 80-150 mL prostates treated for LUTS/BPH, with an expected increase in the risk of complications in larger prostates. Long-term outcomes of procedure durability are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.